Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
Cancers|March 25, 2022
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World StudyJean-Baptiste Assié, Florian Crépin, Emmanuel Grolleau, et al.The Lancet Regional Health. Europe|September 15, 2022
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studiesDidier Debieuvre, Olivier Molinier, Lionel Falchero, et al.Frontiers in Oncology|February 13, 2015
Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working PartyThierry Berghmans, Lieveke Ameye, Jean-Jacques Lafitte, et al.Clinical Lung Cancer|September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart ReviewJürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC studyThomas Pierret, Laurent Greillier, Florian Guisier, et al.Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2023
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS<sup>G12C</sup>-Mutant Lung CancerAli Chour, Julie Denis, Céline Mascaux, et al.Pageof 5